Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.
Roche said Monday that it will take a 56.3-percent stake in Foundation Medicine, Inc. It will buy some 15.6 million existing shares in the Cambridge, Massachusetts-based company for about $780 million and another 5 million newly issued shares for $250 million.
Continue Reading Below
Foundation Medicine offers diagnostic cancer analyses that provide patient-specific data for physicians.
It will retain its operational independence and its chief executive, Michael J. Pellini, will remain in place. The deal foresees investments by Roche that could top $150 million over five years in research and development.